

File No.- BMSIC/40030/555-2025/2533

दिनांक:- 09 / 06 / 2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना
BMSICL की निविदा संख्या- BMSIC/DRUGS/25-03 से संबंधित प्राप्त ई-निविदाओं के तकनीकी
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/25-03**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 66 (छियासठ) ई-निविदा प्राप्त हुई। उक्त 66 (छियासठ) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 16/06/2025 के अपराह्न 05:00 बजे तक केवल e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/555-2025/2533

दिनांक:- 09 / 06 / 2025

प्रतिलिपि :- प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc2 (**www.eproc2.bihar.gov.in**) पर अपलोड करना सुनिश्चित करें।


महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/25-03						
Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids						
Company Name : Modern Laboratories. Total Number of Pages Submitted in bid documents: - 1 to 172						
Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	Yes	19	Yes	-
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	50-55	Yes	-
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	20-27	Yes	-
4	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted. It's Mandatory that The firm should or provide a document for the Unique Department Identification Number (UDIN) for verification of documents.	Yes	40-49	Yes	-
5	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	36-38	Yes	-
6	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	31	Yes	-
7	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	32-34	Yes	-

Arshad Singh


Siddhant

TENDER NO. BMSIC/DRUGS/25-03


Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Modern Laboratories. Total Number of Pages Submitted in bid documents:- 172


Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	61	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	7-9	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	99-132	No	(i) Product approval of NIT sl. No. 12 is not submitted i.e. Co-Trimoxazole Oral Liquid 50 ml. (ii) Pack size of NIT sr. no. 9 is not as per NIT i.e. 4 ml
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	99-132	No	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	66-97 & 134-165	No	MSC of NIT sl. No. 12 is not submitted i.e. Trimoxazole Oral Liquid 50 ml.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	



14/05/25



16/05/25



16/05/25

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	167-171	No	Valid upto 31.10.2024 renewal not submitted.
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	99-132	No	(i) Product approval of NIT sl. No. 12 is not submitted i.e. Co-Trimoxazole Oral Liquid 50 ml. (ii) Pack size of NIT sr. no. 9 is not as per NIT i.e. 4 ml
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	66-97 & 134-165	No	MSC of NIT sl. No. 12 is not submitted i.e. Trimoxazole Oral Liquid 50 ml.
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	4	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	13-16	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	12	Yes	

[Signature]
14/05/2025

[Signature]
16/05/25

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed / Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II .	Yes	2-3	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	10-11	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	35	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	58-60	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	7-9	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	Yes	1	Yes	
21	2(d) Explanation	Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII	Yes	62	Yes	

Shashi
14/05/2025

for *SK*
16/05/25


TENDER NO. BMSIC/DRUGS/25-03

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Modern Laboratories. Total Number of Pages Submitted in bid documents:- 172

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopocial Specification/ Strength		Dosage Form		Pack Size		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	2	Amoxicillin (A) + Clavulanic acid (B)	Amoxycillin & Potassium Clavulanate	250 mg (A) + 50 mg (B)	250 mg + 50	Powder for Injection	Injection	10 ml Vial	Vial	04.03.2017 (page no. 119)	31.12.2026	Generic	Submitted (page no. 66)
2	3	Amoxycillin	Amoxycillin	250 mg	250 mg	DT Tablet	DT Tablet	10 X 10's	Not mentioned	04.03.2017 (page no. 120)	31.12.2026	Generic	Submitted (page no. 81)
3	4	Ampicillin	Ampicillin	250 mg	250 mg	Powder for Injection	Injection	250mg/Vial 20Vials/box	Vial	04.03.2017 (page no. 121)	31.12.2026	Generic	Submitted (page no. 68)
4	5	Cefoperazone Sulbactam	Cefoperazone Sulbactam	1.5gm	1 gm + 0.5 mg	Injection	Injection	10 ml Vial	Vial	04.03.2017 (page no. 122)	31.12.2026	Generic	Submitted (page no. 70)
5	6	Cefotaxime	Cefotaxime	1 g	1000 mg	Powder for Injection	Injection	10 ml Vial	Vial	04.03.2017 (page no. 122)	31.12.2026	Generic	Submitted (page no. 71)
6	7	Chlorhexidine Mouth Wash	Chlorhexidine	0.2 %w/v	0.2%	Mouth wash	Mouth wash	100 ml bottle	Solution	04.03.2017 (page no. 123)	31.12.2026	Generic	Submitted (page no. 95)
7	8	Ciprofloxacin	Ciprofloxacin	0.3%	3 mg/ml	Drops	Eye Drops	5 ml Bottle	Not mentioned	04.03.2017 (page no. 124)	31.12.2026	Generic	Submitted (page no. 95)



14/05/25



16/05/25

8	9	Clindamycin	Clindamycin Injection IP	600mg	150 mg/ml (Product strength not as per NIT)	Injection	Injection	4 ml Vial	4 ml pack size not mentioned not as per NIT	04.03.2017 (page no. 125)	31.12.2026	Generic	Submitted (page no. 73)
9	11	Co-trimoxazole [Trimethoprim (A) + Sulphamethoxazole (B)]	Co-Trimoxazole Tablet IP	160 mg (A) +800 mg (B)	160 mg + 800 mg	Tablet	Tablet	10 Tabs/Strip 10 Strips/Box	Not mentioned	04.03.2017 (page no. 126)	31.12.2026	Generic	Submitted (page no. 86)
10	12	Co-trimoxazole [Trimethoprim (A) + Sulphamethoxazole (B)]	Co-Trimoxazole Tablet IP	40 mg (A) + 200 mg (B)/5 ml	40 mg (A) + 200 mg (B) per tablet (Which is not as per NIT)	Oral liquid	Tablet Not as per NIT	50 ml Bottle 20 Bottles/ Box	Not mentioned	04.03.2017 (page no. 127)	31.12.2026	Generic	Not as per NIT
11	13	Dexamethasone	Dexamethasone Sodium Phosphate Injection IP	4 mg/ml	4 mg/ml	Injection	Injection	2 ml Vial	Not mentioned	04.03.2017	31.12.2026	Generic	Submitted (page no. 73)
12	14	Diclofenac Sodium	Diclofenac Sodium Tablets IP	50 mg	50 mg	Gastro- Resistant Tablet	Enteric Coated	10 x 10	Not mentioned	04.03.2017	31.12.2026	Generic	Submitted (page no. 86)
13	20	Levofloxacin	Levofloxacin Tablets IP	250 mg	250 mg	Tablet	Tablet	10 x 10	Not mentioned	04.03.2017	31.12.2026	Generic	Submitted (page no. 88)
14	25	Piperacillin (A) + Tazobactam (B)	Piperacillin & Tazobactam Injection IP	1 g (A) + 125 mg (B)	1 gm + 125 mg	Powder for Injection	Injection	Vial	Vial	04.03.2017	31.12.2026	Generic	Submitted (page no. 77)
15	26	Piperacillin (A) + Tazobactam (B)	Piperacillin & Tazobactam Injection IP	2 g (A) + 250 mg (B)	2 gm + 250 mg	Powder for Injection	Injection	Vial	Vial	14.09.2020	31.12.2026	Generic	Submitted (page no. 77)

Shashi
14/05/25
SRS
16/05/25



TENDER NO. BMSIC/DRUGS/25-03

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Modern Laboratories. Total Number of Pages Submitted in bid documents:- 172

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	2	Amoxicillin (A) + Clavulanic acid (B)	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
2	3	Amoxycillin	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
3	4	Ampicillin	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
4	5	Cefoperazone Sulbactam	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
5	6	Cefotaxime	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
6	7	Chlorhexidine Mouth Wash	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
7	8	Ciprofloxacin	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025

 14/05/25
 16/05/25

8	9	Clindamycin	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
9	11	Co-trimoxazole [Trimethoprim (A) + Sulphamethoxazole (B)]	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
10	12	Co-trimoxazole [Trimethoprim (A) + Sulphamethoxazole (B)]	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
11	13	Dexamethasone	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
12	14	Diclofenac Sodium	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
13	20	Levofloxacin	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
14	25	Piperacillin (A) + Tazobactam (B)	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025
15	26	Piperacillin (A) + Tazobactam (B)	25 & 28	25/31/89 & 28/17/79	NA	NA	09.05.1979 (page no. 99, 101)	31.12.2026 (page no. 103)	12.04.2022	11.04.2025

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/555-2025/748 dt 25.04.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

Handwritten signature and date:
 16/05/25